Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000945652 | SCV001091692 | benign | not provided | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Department of Otolaryngology – Head & Neck Surgery, |
RCV001375302 | SCV001571876 | uncertain significance | Hearing impairment | 2021-04-12 | criteria provided, single submitter | clinical testing | PP2_Supporting, PP3_Supporting, BS2_Strong |
Ambry Genetics | RCV002545992 | SCV003661828 | uncertain significance | Inborn genetic diseases | 2022-04-06 | criteria provided, single submitter | clinical testing | The c.3251A>C (p.E1084A) alteration is located in exon 37 (coding exon 37) of the COL4A5 gene. This alteration results from a A to C substitution at nucleotide position 3251, causing the glutamic acid (E) at amino acid position 1084 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001832189 | SCV002083657 | likely benign | X-linked Alport syndrome | 2020-04-11 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003933234 | SCV004748036 | likely benign | COL4A5-related disorder | 2023-09-27 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |